www.emjreviews.com/emj-gold/article/pharma-in-the-uk/

London, UK – April 4, 2023 – Paul Jones, CEO of Vortex Biotech Holdings, has been featured in a recent “Pharma in the UK” article, offering his expert perspective on the opportunities and challenges facing the nation’s dynamic pharmaceutical and life sciences sector. The piece, penned by Jade Williams, explores the UK’s position as a global pharma hub amidst evolving economic and healthcare landscapes.

Jones highlighted the UK’s strong foundation in early-stage research and its commitment to innovative health initiatives, such as the UK Biobank and Genomics England. He underscored the potential of these large-scale programs as “proving grounds for getting new and innovative types of technology adopted at a population level,” citing liquid biopsy as a prime example for early cancer detection.

Addressing the current pressures on the NHS, Jones suggested that pharma companies could leverage their resources to support the system more effectively, advocating for a re-evaluation of how drugs are introduced into the NHS. He urged a collaborative approach, with government, the NHS, academia, and industry working together to translate research into clinical systems for patient benefit.

The article also delved into the impact of the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a topic on which Jones stated, “VPAS is not encouraging collaboration. If people are walking away from the table, clearly something has gone wrong.” His insights offer a nuanced view of the UK’s life sciences sector, providing valuable context for Vortex’s strategic positioning within this critical market.